Graves' disease

New England Journal of Medicine

Volumn 343, Issue 17, 2000, Pages 1236-1248

  Weetman, A P ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; CARBIMAZOLE; IMMUNOGLOBULIN G ANTIBODY; IODINE; PROPYLTHIOURACIL; RADIOACTIVE MATERIAL; THIAMAZOLE; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN; THYROTROPIN RECEPTOR;

ADULT; AGRANULOCYTOSIS; ALGORITHM; ARTHRALGIA; AUTOIMMUNITY; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; EXOPHTHALMOS; FEMALE; GENETIC PREDISPOSITION; GOITER; GRAVES DISEASE; HEART PALPITATION; HUMAN; PATHOGENESIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RASH; REVIEW; RISK FACTOR; THYROID CELL; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; URTICARIA;

ANTIBODIES; ANTITHYROID AGENTS; CAUSALITY; DIAGNOSIS, DIFFERENTIAL; FEMALE; GRAVES' DISEASE; HUMAN; HYPERTHYROIDISM; IODINE RADIOISOTOPES; PREGNANCY; PREGNANCY COMPLICATIONS; RECEPTORS, THYROTROPIN; REMISSION INDUCTION; THYROIDECTOMY;

EID: 0034718938     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200010263431707     Document Type: Review

References (94)

1. Abnormal responses in the assay of thyrotrophin
2. Isolation and identification of the long-acting thyroid stimulator and its relation to hyperthyroidism and circumscribed pretibial myxedema
3. The thyrotropin (TSH) receptor: Interaction with TSH and autoantibodies
4. Autoimmunity to the thyroid gland
5. Human thyroid stimulating activity and clinical state in antithyroid treatment of juvenile Graves' disease
6. Pathology
7. Extrathyroidal sites of autoantibody synthesis in Graves' disease
8. Histometry of lymphoid infiltrate in the thyroid of primary thyrotoxicosis patients: Relation of extent of thyroiditis to preoperative drug treatment and preoperative hypothyroidism
9. The thyrotropin receptor in thyroid diseases
10. Monoclonal, human autoantibodies to the TSH receptor - The Holy Grail and why are we looking for it?
11. A mouse monoclonal antibody to a thyrotropin receptor ectodomain variant provides insight into the exquisite antigenic conformational requirement, epitopes and in vivo concentration of human autoantibodies
12. Use of thyrotropin receptor (TSHR) mutants to detect stimulating TSHR antibodies in hypothyroid patients with idiopathic myxedema, who have blocking TSHR antibodies
13. Detection of major T cell epitopes on human thyroid stimulating hormone receptor by overriding immune heterogeneity in patients with Graves' disease
14. Cyclooxygenase-dependent thyroid cell proliferation induced by immunoglobulins from patients with Graves' disease
15. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity
16. Antigen presentation by epithelial cells induces anergic immunoregulatory CD45R0+ T cells and deletion of CD45RA+ T cells
17. Pathogenesis of Graves' ophthalmopathy: Recent controversies and progress
18. Enlargement of levator palpebrae superioris muscle fibers in Graves' ophthalmopathy
19. Is Graves' dermopathy a generalized disorder?
20. Pathogenesis of Graves' ophthalmopathy
21. Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: Potential autoantigen in Graves' ophthalmopathy
22. Development of an animal model of autoimmune thyroid eye disease
23. Role of the eye muscles in thyroid eye disease: Identification of the principal autoantigens
24. What is the evidence of genetic factors in the etiology of Graves' disease? A brief review
25. Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: Replication using a population case control and family-based study
26. HLA-DRB1*08, DRB1*03/DRB3*0101, and DRB3*0202 are susceptibility genes for Graves' disease in North American Caucasians, whereas DRB1*07 is protective
27. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population
28. Linkage analysis of candidate genes in autoimmune thyroid disease. III. Detailed analysis of chromosome 14 localizes Graves' disease-1 (GD-1) close to multinodular goiter-1 (MNG-1)
29. A new Graves' disease-susceptibility locus maps to chromosome 20q11.2
30. Linkage analysis of candidate genes in autoimmune thyroid disease. II. Selected gender-related genes and the X-chromosome
31. Stressful life events and Graves' disease
32. Cigerette smoking and the thyroid
33. Lithium associated thyrotoxicosis: A report of 14 cases, with statistical analysis of incidence
34. Delayed occurrence of Graves' disease after immune restoration with HAART: Highly active antiretroviral therapy
35. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis
36. Infection, thyroid disease, and autoimmunity
37. The epidemiology of autoimmune thyroid disease
38. Epidemiology and estimated population burden of selected autoimmune diseases in the United States
39. Thyrotoxicosis
40. Graves' disease: Influence of age on clinical findings
41. Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance
42. Age and gender influence the severity of thyroid-associated ophthalmopathy: A study of 101 patients attending a combined thyroid-eye clinic
43. Graves' ophthalmopathy in relation to cigarette smoking and ethnic origin
44. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy
45. Dermopathy of Graves' disease (pretibial myxedema): Review of 150 cases
46. Treatment guidelines for patients with hyperthyroidism and hypothyroidism
47. Thyroid nodules in Graves' disease: Classification, characterization, and response to treatment
48. Thyroid controversy - Stimulating antibodies
49. Autoantibodies to the thyrotropin receptor
50. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease
51. Detection of thyroid-stimulating antibody using Chinese hamster ovary cells transfected with cloned human thyrotropin receptor
52. Current management of thyroid-associated ophthalmopathy in Europe: Results of an international survey
53. MR T2 relaxation time for the assessment of retrobulbar inflammation in Graves' ophthalmopathy
54. The role of octreoscan in thyroid eye disease
55. Development of spontaneous hypothyroidism in patients with Graves' disease treated with antithyroidal drugs: Clinical, immunological, and histological findings in 26 patients
56. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy
57. Natural history of thyroid associated ophthalmopathy
58. Quality of life in patients with Graves' ophthalmopathy is markedly decreased: Measurement by the Medical Outcomes Study instrument
59. The management of hyperthyroidism
60. Graves' ophthalmopathy: Current concepts regarding pathogenesis and management
61. Immunomodulatory treatment of Graves' ophthalmopathy
62. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment
63. Antithyroid drugs and Graves' disease - Prospective randomised assessment of long-term treatment
64. Treatment of Graves' disease with the block-replace regimen of antithyroid drugs: The effect of treatment duration and immunogenetic susceptibility on relapse
65. Administration of thyroxine in treated Graves' disease: Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism
66. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug
67. Risk of agranulocytosis and aplastic anaemia in relation to use of antithyroid drugs
68. Screening for agranulocytosis in patients treated with antithyroid drugs
69. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: A prospective study
70. Fifty years of experience with propylthiouracil-associated hepatotoxicity: What have we learned?
71. Current trends in the management of Graves' disease
72. Treatment of Graves' disease: The American way
73. Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: Results from a prospective, randomized study
74. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy
75. Cigarette smoking and treatment outcomes in Graves ophthalmopathy
76. Mortality in patients treated for hyperthyroidism with iodine-131
77. Mortality after the treatment of hyperthyroidism with radioactive iodine
78. Cancer mortality following treatment for adult hyperthyroidism
79. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: A population-based cohort study
80. The management of Graves' disease in children, with special emphasis on radioiodine treatment
81. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: Prevalence, mechanism and prognosis
82. Outcome of thyroid function in Graves' patients treated with radioiodine: Role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage
83. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while?
84. Iodine-131 treatment of hyperthyroidism: Current issues
85. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism
86. Results of subtotal thyroidectomy for Graves' disease
87. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: A case-control study
88. Review of antithyroid drug use during pregnancy and report of a case of aplasia cutis
89. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism
90. A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy
91. A change from stimulatory to blocking antibody activity in Graves' disease during pregnancy
92. Guidelines for TSH-receptor antibody measurements in pregnancy: Results of an evidence-based symposium organized by the European Thyroid Association
93. Treating severe Graves' ophthalmopathy
94. Results of transantral orbital decompression in 428 patients with severe Graves' ophthalmopathy